Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Status:
Not yet recruiting
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, multi-arm phase II platform screening trial designed to test
the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies
simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN).
This Master Study is being conducted as a platform that may allow participants with pain
associated with schwannomatosis to receive a novel intervention throughout this study.
Embedded within the Master Study are individual drug sub-studies:
- Investigational Drug Sub-Study A: Siltuximab
- Investigation Drug Sub-Study B: Erenumab-Aooe
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Recordati Rare Diseases United States Department of Defense